Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
Marc J. M. Bonten(Utrecht University), Diederick E. Grobbee(University Medical Center Utrecht), Emilio A. Emini(United States Military Academy), Marieke Bolkenbaas(University Medical Center Utrecht), Anne McDonough(Pfizer (United Kingdom)), Bas J. Oosterman, Cornelis H. van Werkhoven(University Medical Center Utrecht), Rita Lobatto, Scott D. Patterson(Gilead Sciences (United States)), Nils L. Visser, Theo Verheij(Utrecht University), Elisabeth A. M. Sanders(Wilhelmina Children's Hospital), Tracey Mellelieu(Pfizer (United Kingdom)), Esther Caspers, Anna M.M. van Deursen(University Medical Center Utrecht), Graham Crowther(Pfizer (United Kingdom)), Samantha Gault(Pfizer (United Kingdom)), Helen Smith, Andre Smorenburg, Michael W. Pride(Pfizer (United States)), William C. Gruber(Pfizer (United States)), Beate Schmöele-Thoma(Pfizer (Germany)), Daniel A. Scott(Naval Medical Research Command), Kathrin U. Jansen(Pfizer (United States)), Michael A. Patton(St George's Hospital), Susanne M. Huijts(University Medical Center Utrecht), Chris Webber(Pfizer (United Kingdom)), Anita Moradoghli-Haftvani(Pfizer (United Kingdom))
Cited by 1,237
Related Papers
Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
|BMJ|2020|3.2k
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
|New England Journal of Medicine|1997|1.9k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
Prognosis and prognostic research: what, why, and how?
|BMJ|2009|1.4k